
Nutra Pharma Announces Manufacturing Alliance with Omnia Biologics to Produce RPI-78M for Clinical T
September 14, 2016 September 14, 2016 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a manufacturing alliance today with Omnia Biologics to clone and produce alpha-cobratoxin for the produc